Related Experiment Video
Updated: May 12, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
Published on: April 15, 2017
A public-private consortium advances cardiac safety evaluation: achievements of the HESI Cardiac Safety Technical
Jennifer B Pierson1, Brian R Berridge, Marjory B Brooks
1Health and Environmental Sciences Institute, 1156 15th Street, Northwest, Suite 200, Washington, DC 20005, USA.
Insights
The HESI Technical Committee on Cardiac Safety improved drug development by fostering collaboration. This international consortium enhanced cardiac safety strategies and resource sharing, leading to better pharmaceutical safety.
Area of Science:
- Pharmacology and Toxicology
- Drug Development
- Cardiovascular Safety
Background:
- Cardiovascular side-effects are critical in drug and chemical development.
- Cardiac safety issues frequently cause drug attrition and withdrawal due to adverse drug reactions (ADRs).
Purpose of the Study:
- To present the evolution of the HESI Technical Committee on Cardiac Safety (2000-2013).
- To highlight the committee's role as an international consortium improving cardiac safety.
Main Methods:
- Describing the formation and activities of the HESI Technical Committee on Cardiac Safety.
- Illustrating the collaborative efforts of academic, government, and industry scientists.
Main Results:
- The HESI Technical Committee Working Groups fostered resource sharing and expert communication.
- Innovative strategies for improved drug safety were developed through these collaborations.
Conclusions:
- International collaboration through consortia like HESI is vital for advancing drug safety.
- The HESI Technical Committee's work exemplifies successful strategies for mitigating cardiac risks in drug development.
Introduction:
The evaluation of cardiovascular side-effects is a critical element in the development of all new drugs and chemicals. Cardiac safety issues are a major cause of attrition and withdrawal due to adverse drug reactions (ADRs) in pharmaceutical drug development.
Methods:
The evolution of the HESI Technical Committee on Cardiac Safety from 2000-2013 is presented as an example of an effective international consortium of academic, government, and industry scientists working to improve cardiac safety.
Results And Discussion:
The HESI Technical Committee Working Groups facilitated the development of a variety of platforms for resource sharing and communication among experts that led to innovative strategies for improved drug safety. The positive impacts arising from these Working Groups are described in this article.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiopulmonary Resuscitation III: AED Use
Cardiac Catheterization II: Right Heart Catheterization
Cardiac Catheterization IV: Nursing Management
